<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03839511</url>
  </required_header>
  <id_info>
    <org_study_id>2018-050-PBRC HYPOCLAMP</org_study_id>
    <nct_id>NCT03839511</nct_id>
  </id_info>
  <brief_title>Use of a Hyperinsulinemic-hypyglycemic Clamp to Study Hypoglycemia: a Method Development Study</brief_title>
  <official_title>Use of a Hyperinsulinemic-hypyglycemic Clamp to Study Hypoglycemia: a Method Development Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pennington Biomedical Research Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A hyperinsulinemic-hypoglycemic clamp is an experimental procedure, which allows for
      hypoglycemia to be studied in a safe and controlled manner. The goal of this study is to
      establish the hyperinsulinemic-hypoglycemic clamp procedure at Pennington Biomedical Research
      Center in order to apply the knowledge gained to future studies which will determine the
      efficacy of our biomarker for predicting susceptibility to hypoglycemia. Additionally, our
      use of continuous glucose monitoring (CGM) during the clamp procedure will provide novel data
      regarding the accuracy of CGM during hypoglycemic conditions in a controlled research
      setting.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 28, 2018</start_date>
  <completion_date type="Anticipated">December 16, 2020</completion_date>
  <primary_completion_date type="Actual">December 16, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Epinephrine levels</measure>
    <time_frame>180 minutes</time_frame>
    <description>Serum epinephrine levels will be measure before and after induction of hypoglycemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGM glucose</measure>
    <time_frame>220 minutes</time_frame>
    <description>continuous glucose monitoring device glucose readings</description>
  </secondary_outcome>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Diabetes</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperinsulinemic-hypoglycemic clamp</intervention_name>
    <description>Subjects will arrive at the inpatient unit in the morning after at least a 10 hour overnight fast. Upon arrival to PBRC, participants will be admitted to the inpatient unit. Following measurement of weight, vitals, and pregnancy test (women only), the 4-hour hypoglycemic clamp procedure (30 minute baseline, 120 minute insulin infusion, and 90 minute recovery) will be performed. Upon completion of the clamp procedure, participants will be provided lunch (Standard American Diet). Following lunch, the CGM sensor will be removed and pending a stable blood glucose level in the normal range, the participant will be discharged from the inpatient unit. This completes the study.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We will enroll up to 8 healthy men or women (goal n=3 completers) in this method
        development study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female

          -  Ages 18-40 years

          -  BMI between 20 kg/m2 and 30 kg/m2 (Â±0.5 kg/m2 will be accepted)

          -  Medically cleared for participation in the study

        Exclusion Criteria:

          -  History of clinically diagnosed diabetes or a fasting blood glucose &gt;126 mg/dL

          -  Average screening blood pressure &gt;140/90 mmHg

          -  History of cardiovascular disease

          -  Pregnant, planning to become pregnant, or breastfeeding

          -  Based on the investigative team's clinical judgement, a subject may not be appropriate
             for participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808-4124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>June 7, 2020</last_update_submitted>
  <last_update_submitted_qc>June 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pennington Biomedical Research Center</investigator_affiliation>
    <investigator_full_name>David McDougal</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03839511/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

